Business Wire

IFF Tackles Top Challenges in Baking at IBIE 2025

2.9.2025 13:00:00 CEST | Business Wire | Press release

Share

From commodity volatility to new regulations, IFF readies bakers with science-driven innovations and real-world demos.

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, health and biosciences, will showcase how it is helping the global baking industry overcome some of its toughest challenges at the International Baking Industry Exposition (IBIE) 2025 in Las Vegas. From soaring cocoa and egg prices to stricter regulations and rising demand for healthier baked goods, IFF is stepping forward with bold, science-led solutions designed to keep industrial bakers ahead of the curve.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902465856/en/

“The industry is under pressure from every direction — supply chains, regulations and consumer expectations,” said Suzanne Pera, vice president and regional general manager for North America, IFF Food Ingredients. “Our message at IBIE is simple: Bakers don’t have to face these challenges alone. We bring unmatched expertise across the entire process, from formulation to shelf. We’re not just helping bakers adapt — we’re helping them win.”

Addressing the cost of volatility

With cocoa prices doubling and egg supplies remaining strained, IFF CURE™ — a comprehensive suite of Core and Uncommon Replacements and Extenders — offers solutions that maintain taste and texture while reducing reliance on volatile commodities. At the booth, visitors can sample 50 percent egg-reduced cupcakes and 30 percent cocoa-reduced brownies made with proprietary enzyme blends, system blends and natural flavors.

Navigating regulatory shifts

With certain food dyes now banned and the industry reevaluating what quantifies as “healthy,” bakers face increasing reformulation demands. IFF spotlights natural color alternatives, label-friendly hydrocolloids and shelf-life extension solutions that keep products compliant without sacrificing sensory appeal.

Meeting the health-conscious consumer

GLP-1 users are reshaping food and beverage demand, while shoppers broadly seek lower sugar, more protein and label-friendly bakery options. The prototypes reflect how IFF translates consumer and regulatory insights into market-ready products, featuring better-for-you concepts like high-protein tortillas and consumer-validated nutrition bars fortified with SOLAE® SUPRO® soy protein and LITESSE® ULTRA prebiotic fiber.

Breakthrough baking technologies debut

IFF will debut DANISCO® GRINDSTED® Pectin FB 420, a bake-stable pectin made from citrus peels. This naturally sourced, label-friendly alternative to starch enhances flavor release and mouthfeel, while delivering a bright, glossy texture in reduced-sugar bakery applications. Also launching is POWERFRESH® ACE 2000, a next-generation fresh-keeping enzyme that improves bread softness, resilience and cohesiveness for up to 34 days.

“We are not just displaying ingredients,” said Linda Dunning, applications director, North America, IFF Food Ingredients. “We are showing how real-world solutions can raise the game for bakers — ideas that work in the lab, are scalable in production and stand out on the shelf.”

Attendees will experience go-to-market applications, designed to inspire product innovations while solving some of the baking industry’s toughest challenges. IFF will be at IBIE 2025 from Sept. 14-17 at the Las Vegas Convention Center, booth 3855.

To learn more about IFF at IBIE and its bold, future-forward baking solutions, visit the IFF IBIE 2025 page here.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250902465856/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye